<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03746327</url>
  </required_header>
  <id_info>
    <org_study_id>PROTEDI 2018-002465-18</org_study_id>
    <nct_id>NCT03746327</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance of 4 Weeks of Tedizolid in Prosthetic Joint Infections Treated With Implant Removal</brief_title>
  <acronym>PROTEDI</acronym>
  <official_title>English Efficacy and Tolerance of 4 Weeks of Tedizolid in Prosthetic Joint Infections Treated With Implant Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of 4 weeks of 200 mg/24h of tedizolid for prosthetic join infections&#xD;
      caused by tedizolid susceptible microorganisms treated with implant removal in one or two&#xD;
      stages at 6 months of followup after stopping tedizolid treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy of 4 weeks of 200 mg/24h of tedizolid for prosthetic join infections&#xD;
      caused by tedizolid susceptible microorganisms treated with implant removal in one or two&#xD;
      stages at 6 months of followup after stopping tedizolid treatment.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      Evaluate the efficacy of tedizolid at 12 months of follow-up; evaluate the rate of&#xD;
      gastrointestinal adverse events with tedizolid; determine the rate of haematological&#xD;
      abnormalities during tedizolid treatment and; in case of two-stage exchange, the rate of&#xD;
      positive cultures during reimplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator-assessed incidence of local signs infection at 6 months after tedizolid</measure>
    <time_frame>6 months</time_frame>
    <description>incidence or absence of local signs of infection at the 6 months after tedizolid treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events at 12 months after ending tedizolid treatment</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of adverse events at the 12 months after tedizolid treatment. number of Adverse Events as assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of positive blood cultures during reimplantation on the two stage exchange cases.</measure>
    <time_frame>0, 7 days and months 1, 2, 6, 12</time_frame>
    <description>incidence blood cultures at reimplantation,</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostheses Infection</condition>
  <arm_group>
    <arm_group_label>Sivextro arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg milligram per day during 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sivextro 200 milligrams Oral Tablet</intervention_name>
    <description>200 mg milligram per day during 4 weeks</description>
    <arm_group_label>Sivextro arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female older than 18 years who accept and sign the informed consent.&#xD;
&#xD;
          2. Infection signs onset more than 3 months after index arthroplasty.&#xD;
&#xD;
          3. Diagnostic of chronic (≥3 weeks of clinical symptoms) hip or knee prosthetic joint&#xD;
             infection according to MSIS criteria *(Parvizi J, Gherke T. Definition of&#xD;
             peri-prosthetic joint infection. J Arthroplasty 2014; 29: 1331)&#xD;
&#xD;
          4. Infection due to a tedizolid susceptible microorganism.&#xD;
&#xD;
          5. Surgical approach: one or two - stage exchange of all implant components.&#xD;
&#xD;
          6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a prosthetic joint infection with negative cultures.&#xD;
&#xD;
          2. Patients who undergo debridement without removing the prosthesis or only partially&#xD;
             removed&#xD;
&#xD;
          3. ≥15 days of other antibiotic treatment before starting tedizolid&#xD;
&#xD;
          4. Life expeancy ≤ 1 year.&#xD;
&#xD;
          5. Previous enrollment in this protocol.&#xD;
&#xD;
          6. Hypersensitivity to tedizolid or any formulation excipients.&#xD;
&#xD;
          7. Concurrent use of another investigational medication within 30 days of study entry.&#xD;
&#xD;
          8. Women who are pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Anna Cruceta</investigator_full_name>
    <investigator_title>Project manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tedizolid phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

